Delta NT-proBNP: Better Marker of Neuroendocrine Pathways Blockade in Decompensated Congestive Heart Failure?

Congestive heart failure (CHF) constitutes a major disorder affecting a large number of patients within the U.S. and its territories. Worldwide, CHF is the leading cause of hospital admissions among patients aged > 65 years.(1) A 2010 update from the American Heart Association (AHA) estimated that there were 5.8 million people with heart failure (HF) in the U.S. in 2006.(1) Furthermore, the use of biomarkers within the cardiology field has increased in popularity.